Jennifer E. Amengual

2.3k total citations
87 papers, 1.1k citations indexed

About

Jennifer E. Amengual is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Jennifer E. Amengual has authored 87 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 43 papers in Pathology and Forensic Medicine and 37 papers in Oncology. Recurrent topics in Jennifer E. Amengual's work include Lymphoma Diagnosis and Treatment (43 papers), Histone Deacetylase Inhibitors Research (24 papers) and Protein Degradation and Inhibitors (16 papers). Jennifer E. Amengual is often cited by papers focused on Lymphoma Diagnosis and Treatment (43 papers), Histone Deacetylase Inhibitors Research (24 papers) and Protein Degradation and Inhibitors (16 papers). Jennifer E. Amengual collaborates with scholars based in United States, Australia and United Kingdom. Jennifer E. Amengual's co-authors include Jennifer Kimberly Lue, Owen A. O’Connor, Luigi Scotto, Serge Cremers, Enrica Marchi, Ahmed Sawas, Matko Kalac, Changchun Deng, Kelly Zullo and Govind Bhagat and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jennifer E. Amengual

84 papers receiving 1.0k citations

Peers

Jennifer E. Amengual

PFM

ONCOL

IMMUN

GENET

Daniela Buglio United States

Kedar Inamdar United States

Barbara MacGregor‐Cortelli United States

Marion Travert France

Amanda Copeland United States

J-Y Chen Taiwan

Cecilia Kelly United States

Laurence Cooke United States

Y. Terui Japan

Maria B. Karpova Switzerland

Daniela Buglio United States

Jennifer E. Amengual

745 ×1.3

447 ×1.0

PFM

454 ×1.1

ONCOL

188 ×0.9

IMMUN

205 ×1.5

GENET

Citations per year, relative to Jennifer E. Amengual Jennifer E. Amengual (= 1×) peers Daniela Buglio

Countries citing papers authored by Jennifer E. Amengual

Since Specialization

Citations

This map shows the geographic impact of Jennifer E. Amengual's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer E. Amengual with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer E. Amengual more than expected).

Fields of papers citing papers by Jennifer E. Amengual

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer E. Amengual. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer E. Amengual. The network helps show where Jennifer E. Amengual may publish in the future.

Co-authorship network of co-authors of Jennifer E. Amengual

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer E. Amengual. A scholar is included among the top collaborators of Jennifer E. Amengual based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer E. Amengual. Jennifer E. Amengual is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolu, Seda S., et al.. (2025). Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas. Blood. 146(Supplement 1). 3558–3558.

Peña‐Bautista, Carmen, Jennifer E. Amengual, Miquel Baquero, et al.. (2025). New approach to specific Alzheimer's disease diagnosis based on plasma biomarkers in a cognitive disorder cohort. European Journal of Clinical Investigation. 55(8). e70034–e70034. 1 indexed citations

Pazos, Manuel, et al.. (2024). Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma. Blood. 144(Supplement 1). 973–973. 1 indexed citations

Amengual, Jennifer E., Aung M. Tun, Victor Yazbeck, et al.. (2024). Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma. Blood. 144(Supplement 1). 3112–3112. 2 indexed citations

Tolu, Seda S., et al.. (2024). Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas. Blood. 144(Supplement 1). 336–336. 1 indexed citations

Amengual, Jennifer E. & Barbara Pro. (2023). How I treat posttransplant lymphoproliferative disorder. Blood. 142(17). 1426–1437. 11 indexed citations

Chen, Xiao, Yinglu Li, Fang Zhu, et al.. (2023). Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma. Nature Communications. 14(1). 4259–4259. 12 indexed citations

Amengual, Jennifer E., Patrick M. Reagan, Hayder Saeed, et al.. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology. 41(S2). 842–843. 1 indexed citations

Lue, Jennifer Kimberly, Sathyen A. Prabhu, Yuxuan Liu, et al.. (2019). Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. Clinical Cancer Research. 25(17). 5271–5283. 59 indexed citations

10.

Liu, Yuxuan, et al.. (2019). Chromatin-Remodeled State in Lymphoma. Current Hematologic Malignancy Reports. 14(5). 439–450. 5 indexed citations

11.

Ma, Helen, Ardalan Davarifar, & Jennifer E. Amengual. (2018). The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). Current Hematologic Malignancy Reports. 13(1). 13–24. 22 indexed citations

12.

Sawas, Ahmed, Charles M. Farber, Marshall T. Schreeder, et al.. (2017). A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. British Journal of Haematology. 177(2). 243–253. 61 indexed citations

13.

Amengual, Jennifer E., Jennifer Kimberly Lue, Ahmed Sawas, et al.. (2017). A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 131(4). 397–407. 91 indexed citations

14.

Falchi, Lorenzo, Jennifer Kimberly Lue, Jennifer E. Amengual, et al.. (2017). A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL). Blood. 130. 1515–1515. 10 indexed citations

15.

Amengual, Jennifer E., Sathyen A. Prabhu, Maximilian Lombardo, et al.. (2016). Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. Clinical Cancer Research. 23(12). 3084–3096. 24 indexed citations

16.

Jain, Salvia, Kelly Zullo, Luigi Scotto, et al.. (2015). Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clinical Cancer Research. 21(9). 2096–2106. 49 indexed citations

17.

Amengual, Jennifer E., Paul Johannet, Maximilian Lombardo, et al.. (2015). Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clinical Cancer Research. 21(20). 4663–4675. 71 indexed citations

18.

Zullo, Kelly, Laurence Cooke, Luigi Scotto, et al.. (2015). Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma. Clinical Cancer Research. 21(18). 4097–4109. 33 indexed citations

19.

Amengual, Jennifer E., et al.. (2015). Will new drugs change the standard of care for patients with mantle cell lymphoma?. Expert Review of Anticancer Therapy. 16(2). 199–210. 1 indexed citations

20.

Scotto, Luigi, Marianna Kruithof‐de Julio, Luca Paoluzzi, et al.. (2012). Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas. Clinical Cancer Research. 18(14). 3803–3811. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact